Endovia Health Sciences (EDVA): +12% Rebound Highlights Micro-Cap Volatility

Key Takeaways

• EDVA has climbed roughly 12% over the past 30 days, rebounding from a 52-week intraday low of $0.1344 set in mid-October 2026.
• The gain is a short-term bounce within a steep downtrend — the stock is still down about 55% over the past quarter and more than 90% year to date.
• The company recently rebranded from Splash Beverage Group to Endovia Health Sciences, pivoting from beverages into a cannabinoid health-sciences platform.
• Thin liquidity, a market capitalization near $2 million, and outstanding going-concern risk keep EDVA unusually volatile.
• Verified drivers include the corporate transformation, convertible-debt funding, and dilution concerns tied to an expanded equity incentive plan.
• For additional context, review EDVA's Price Targets, Earnings, and Forecast pages on Tickeron.
• Explore Trending AI Robots to browse AI-driven trading bots active across the market.

Endovia Health Sciences (EDVA) Company Background

Endovia Health Sciences, Inc. (EDVA) is a Fort Lauderdale, Florida-based micro-cap company transitioning from a beverage distributor into a cannabinoid health-sciences business. The company was previously known as Splash Beverage Group and marketed brands including SALT Tequila, Chispo Tequila, Copa di Vino, and Pulpoloco Sangria. Following a rebrand effective August 24, 2026, the company is now focused on CannEpil, a pharmaceutical-grade oral-liquid formulation combining CBD and THC isolates, aimed at regulated human and animal health markets in Ireland, the United Kingdom, Australia, and Latin America. Investors follow the stock for its high-risk pivot into regulated therapeutics and its speculative, thinly traded micro-cap profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

EDVA Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, EDVA has gained roughly 12%, rebounding from a 52-week intraday low of $0.1344 set on October 15, 2026. The shares recently traded near $0.19. Over the last quarter, however, the trend is sharply different: the stock is down about 55%, extending a year-to-date decline of more than 90%. The shares sit far below a 52-week high of $6.76 reached in December 2025. This divergence — a short-term rebound inside a much longer downtrend — underscores the stock's extreme micro-cap volatility. From what I see, this pattern is typical for names with limited liquidity.

What Drove EDVA Stock Price in the Last 30 Days

The 30-day advance was driven primarily by a technical rebound from deeply oversold levels rather than any single fundamental catalyst. After touching $0.1344 in mid-October, bargain-hunting and speculative interest lifted the shares in thin trading, a pattern common among micro-caps where relatively small order flows can produce outsized percentage moves. Supporting the move, the company has continued executing its transformation into a cannabinoid health-sciences platform, a narrative that periodically attracts speculative demand. During the period the company also advanced its capital-raising and regulatory filings, building on the initial $500,000 tranche of a $1 million convertible-debt commitment secured in late September 2026 to fund development of CannEpil. Those financing activities cut both ways, however — new capital helps fund operations, while the associated share issuance and an expanded equity incentive plan have raised dilution concerns among existing holders.

What Drove EDVA Stock Performance Over the Last Quarter

The quarterly decline of roughly 55% reflects the market's re-rating of a company that has fundamentally changed its identity. EDVA completed its rebrand from Splash Beverage Group and began trading under the EDVA ticker in late August 2026, shifting from an established beverage business into a capital-intensive, highly regulated pharmaceutical and wellness endeavor. That pivot introduced significant execution and regulatory risk. Compounding the pressure, the company disclosed in September proposed amendments to its 2025 Equity Incentive Plan — including roughly 4.8 million additional shares and an "Automatic Ownership Maintenance" mechanism — which it acknowledged could cause substantial, ongoing dilution. Auditors have also expressed substantial doubt about the company's ability to continue as a going concern, citing recurring losses, a net loss of $25.3 million in fiscal 2025, minimal revenue, and limited cash. These factors have kept the stock under sustained downward pressure even as it stages short-term rebounds.

EDVA Stock Forecast Drivers: What Investors Should Watch Next

Several factors will likely shape EDVA going forward. First, the company's next quarterly report is expected in late November 2026, and its results and guidance will be closely watched given the company's thin cash position. Second, capital-raising and share issuance will remain central: additional convertible-debt draws or equity sales could fund development but also dilute existing holders. Third, regulatory progress on CannEpil — including any clinical or FDA-related milestones — will test the core investment thesis. Fourth, continued listing compliance on NYSE American is a practical risk given the company's small capitalization and financial strain. Finally, broader sentiment toward micro-cap and cannabinoid-related equities may influence trading. Investors should weigh these factors against the stock's already extreme volatility and the company's going-concern disclosure. One thing that stands out is how quickly sentiment can shift in this space.

Using Tickeron AI Tools for Market Insights

In my own research process, I often turn to Tickeron’s AI tools to scan for patterns and compare opportunities across sectors. The Trending AI Robots page, for example, surfaces a focused selection of automated strategies that have shown relevance in recent market conditions. It serves as a practical discovery tool for those looking to incorporate data-driven approaches without needing to build systems from scratch. I’m watching this closely as a way to add discipline to monitoring volatile names like EDVA.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume